I came up with this soft, more on a cool side gimp processing that I really like so I thought I would share. This is just a simple way to cool down your photo a bit. I named the processing Waves because it kinda reminds me of the salty sea and underwater, kinda. So yeah. Again, this might need a bit of tweaking on your part. This is just for this image and its exposure values/light. Oh, and the tool I used is curves. I promise to post more of this tutorials. Not just the simple ones.
Thank you Ines. Your processing is simple but effective. The picture rendered by your camera looks nice too. After a little talk with you, I downloaded GIMP again and tried it out. As a Photoshop user I have to say that many things you can do with Photoshop, you can do with GIMP too. I just dont know if there is a addon that delivers a Exclusion blend mode, this is very nice to have when aiming a vintage look.


This entry was posted on April 18, 2019 and tagged Pet, Puppies Picture, Pups.
This entry was posted on April 16, 2019 and tagged Cute Dog Pictures, Love, Pet Picture.
This entry was posted on April 15, 2019 and tagged Animal Picture, Dog Pics, Puppy Pics.


text:
Rising Survival Rates With Hodgkin Lymphoma
More in Lymphoma
Understanding Your Prognosis With Hodgkin Disease
By Lynne Eldridge, MD
If you or a loved one are living with Hodgkin lymphoma, you have probably wondered about the survival rates from the disease. Hodgkin lymphoma often affects young people during some of the most productive times of their lives. Amidst juggling jobs and as parents of young children, many people with the disease have questions about the "expected" life expectancy. Thankfully, Hodgkin disease (the older name for this cancer) is one of the most curable forms of cancer.
At the same time that you're probably encouraged by hearing survival rates with Hodgkin lymphoma, it's easy to be skeptical upon hearing yet another headline announcing the "advancements" in treatment. The good news is that—with regard to Hodgkin anyway—this is not just hype or false hope. We will talk about how the life expectancy has improved over time historically, and what treatments have made the difference.
Some of the confusion when talking about survival with blood-related cancers such as Hodgkin lymphoma stems from what people know about other cancers, such as breast cancer. People are often familiar with how breast cancer may recur years or even decades after treatment. With Hodgkin lymphoma, most recurrences occur early on, and these late relapses are uncommon. In other words, those who have survived 5 years with Hodgkin lymphoma are more likely to be long-term survivors than are people with most solid tumors.
Let's talk about the current survival statistics with Hodgkin lymphoma, factors which may affect life expectancy from stage to age at diagnosis, and what you can do yourself to hopefully improve your prognosis.
Hodgkin Lymphoma: A Brief Review
Hodgkin lymphoma is a cancer of the lymphatic system, a part of the immune system. It often occurs in young adults with two peaks in diagnosis; one between the ages of 15 and 35 and another in people over the age of 55. Hodgkin disease generally begins with the painless enlargement of lymph nodes anywhere in the body, but often in the neck. There are five different types of Hodgkin lymphoma which differ in frequency, the part of the body that they affect, and how they respond to treatment.
A Historical Perspective on the Prognosis of Hodgkin Lymphoma
Hodgkin lymphoma is one of the most "curable" cancers, but this has not always been the case. First recognized in the 19th century, the prognosis until the middle of the last century was poor, with the 5-year survival rate being a dismal 10 percent.
With the advent of radiotherapy, and then combination chemotherapy in the 1960s, the prognosis for the disease improved dramatically, and almost overnight at least half of the people diagnosed were surviving the disease.
Yet improvements in treatment continue. From data released by the National Cancer Institute in April of 2017, the 5-year survival rate for Hodgkin lymphoma (all stages combined) was 69.9 percent in 1975 and 85.4 percent in 2009. Much of this increase is due to advancements in chemotherapy (such as ABVD chemotherapy, and the BEACOPP chemotherapy regimen), radiation therapy, and stem cell therapy.
Survival rates continue to improve, and though rates are significantly lower for those who are diagnosed at older ages or who have more advanced stages of the disease, these are now improving as well. The use of high-dose salvage chemotherapy and stem cell transplantation for those who experience a relapse have further improved survival. The use of targeted therapy with monoclonal antibodies, immunotherapy with checkpoint inhibitors, and nonmyeloablative stem cell transplants offer additional methods of treatment expected to further improve survival in those with more difficult-to-treat Hodgkin lymphomas.
Better management of complications, such as infections related to chemotherapy-induced neutropenia (low white blood cell count), has also been making a difference.
Survival is not the only benefit of improved treatments. Less toxic chemotherapy and small field radiation therapy have been reducing the side effects of treatment and, it's hoped, the long-term side effects of the disease.
Survival With Blood-Related Cancers vs. Solid Tumors
For those who are more familiar with cancers such as breast cancer, it's helpful to take a moment and talk about how the advanced stages (stage III or stage IV) of Hodgkin disease (and some other blood-related cancers) are different prognostically than the advanced stages of many solid tumors (such as breast cancer or pancreatic cancer).
Advanced blood-related cancers, such as stage IV Hodgkin disease, are often still curable. In contrast, most advanced stage solid tumors (such as stage IV breast cancer or stage IV pancreatic cancer) are not curable. Likewise, the prognosis of relapsed Hodgkin lymphoma is also much better than a recurrence of most solid tumors.
Understanding Survival Rates and Life Expectancy Estimates
We will get to the numbers and statistics describing survival shortly but need to define what these rates mean, and some of the limitations inherent in these statistics.
Survival rates are usually described as a percentage followed by a certain amount of time. For example, you may see 1-year, 5-year, or 10-year survival rates. If a disease has a 5-year survival rate it means that 50 percent of people with the disease will be alive 5 years after diagnosis.
Sometimes you may instead see the term "median survival rate." A median survival rate is followed by an amount of time and represents the time after which 50 percent of people would have died and 50 percent of people are still alive. For example, a median survival rate of 13 months would be time after which 50 percent of people have died and 50 percent are still alive. With cancers such as Hodgkin disease, you will see survival rates more often, whereas, with cancers such as pancreatic cancer or lung cancer, median survival is often used.
In looking at these rates, the most important point to make is that they are "averages" and "numbers." Real people aren't statistics. These numbers describe how long someone with any stage of Hodgkin disease and any other factors is expected to live. Yet, even when survival rates are broken down by age and stage, it is impossible to predict how an individual person will do with the disease. Some people do much better than the "average" and some people do not.
Limitations of Survival Rates
As noted above, one of the greatest limitations of survival rates is that they give an average estimate of survival, but nobody is average. In addition, survival rates can be misleading for other reasons.
Looking at 5-year survival rates means we are looking at people who were diagnosed at least 5 years ago. During that time, new treatments have often been developed. At best, survival rates can tell you how the average person did in the past after being treated with therapies that may or may not even be used today. With the advances taking place in cancer treatment, survival rates are becoming less accurate as an estimate in the past. While this can make predictions more difficult, it tells us progress is being made.
Long-term survival is even harder to predict. Many studies distinguish deaths due to Hodgkin disease and deaths due to other causes, yet these measures don't always take into account medical conditions which are unrelated but due to treatment, such as secondary cancers.
Overall Survival Rates and Survival Rate by Stage
There are many different ways of looking at survival rates with Hodgkin lymphoma. Let's look at these in a few ways.
Overall survival rates giving the life expectancy for people with all stages combined include:
1–year overall survival rate of 92 percent
5-year overall survival rate of 87 percent
10-year overall survival rate of 80 percent
5-year survival rates by stage include:
Stage I 5-year survival rate is 90 percent
Stage II 5-year survival rate is 90 percent
Stage III 5-year survival rate is 80 percent
Stage IV 5-year survival rate is 65 percent
It's important to note that these rates are an average of all people with a certain stage of Hodgkin disease no matter their age and regardless of other factors that may increase or decrease the chance of survival.
Long-Term Survival With Hodgkin Lymphoma
Long-term survival with Hodgkin lymphoma is difficult to estimate, due to conditions such as secondary cancers which may occur decades after treatment. That said, different studies estimate that somewhere between 15 and 30 years out from treatment, people who have had Hodgkin lymphoma are more likely to die from a cause unrelated to Hodgkin lymphoma than from Hodgkin. In other words, after this period of time people are likely to die of causes that the average public would die from.
Factors Which Affect Survival With Hodgkin Disease
There are many variables which are associated with either an increased or decreased chance of surviving Hodgkin disease. Some of these include:
The stage of the disease – Stage I or II disease carries a better prognosis than stage III or stage IV.
Age – Younger people tend to do better than those who are older (over the age of 45).
Sex – Women tend to have a higher life expectancy than men.
The presence of B symptoms – Weight loss, night sweats, and fevers, the so-called B symptoms of lymphoma, are associated with a poorer prognosis (but still, most people can achieve long term survival).
Whether a relapse occurs and when – For those who have a relapse in the first year following treatment, the prognosis is poorer.
Response to treatment – Those who respond to first-line therapy have a better prognosis than those who do not.
Albumin level – A low albumin level (less than 4 g/dL) is associated with a poorer prognosis.
White blood cell count (WBC) – An elevated white blood cell count (greater than 15,000 blood cells per mm3) is associated with a poorer prognosis.
Low absolute lymphocyte count (ALC) – An absolute lymphocyte count less than 600 cells per mm3 is associated with a poorer prognosis.
Less bulky disease has a better prognosis.
Anemia – A low hemoglobin (less than 10.5 g/dL) is linked with a poorer prognosis than those with a higher hemoglobin level.
Sed rate - An erythrocyte sedimentation rate (ESR) greater than 30 is associated with a poorer prognosis.
The type of Hodgkin lymphoma – Some types of Hodgkin lymphomas are associated with a better survival rate than others (nodular lymphocyte predominant and nodular sclerosing types have a better prognosis in general).
General health at the time of diagnosis and other medical conditions
Whether the cancer is recurrent or progressive
Health insurance – People who do not have health insurance have a poorer prognosis.
Secondary cancers: People who have been treated for Hodgkin lymphoma have an increased risk of developing a secondary cancer, a cancer related to the carcinogenic effects of chemotherapy and/or radiation.
Secondary Cancers in Survivors of Hodgkin Lymphoma
Recurrence and Survival Rates
As we noted above, the timing and frequency of recurrences are much different with Hodgkin lymphoma than with breast cancer. With Hodgkin lymphoma, more than half of recurrences occur within 2 years of the primary treatment and up to 90 percent occur before the 5-year mark. The occurrence of a relapse after 10 years is rare and after 15 years the risk of developing lymphoma is the same as its risk in the normal population. For those who have heard about breast cancers recurring after many years, it may come as some reassurance that this is uncommon with Hodgkin disease. It's also important to note that even with a recurrence, many people with Hodgkin disease will go on to live long lives.
Estimating Your Prognosis
For those wish to have a better idea about their estimated prognosis, there is a tool known as the Hasenclever prognostic tool which is used to estimate prognosis based on seven different factors or risks. Each of these seven factors is thought to reduce 5-year survival by roughly eight percent. These include a serum albumin less than 40 g/dL, a hemoglobin less than 10.5 g/dL, male sex, stage IV disease, a white blood cell count over 15,000/mL, and a lymphocyte count less than 600/mL.
For those without any of these risk factors, the 5-year estimated prognosis (overall) is 89 percent, and for those with 5 or more risk factors, the estimated 5-year survival rate is 56 percent.
Keep in mind that these tools are again used to estimate "average" prognosis, and nobody is average. It's also important to note that even if you have five or more risk factors, the majority—over 50 percent of people—are still alive 5 years after diagnosis.
What Can You Do to Improve Your Prognosis?
With all of the discussions about treatment options, it's sometimes easy to forget that there are simple things you can do yourself to improve your prognosis. It's important to:
Eat healthy: What you put in your body can make a difference in how well you tolerate treatments and how well you feel after treatment. If you are having any difficulties, ask your oncologist to set you up with an oncology nutritionist.
Exercise: We now have a multitude of studies that have looked at the effect of regular exercise on the outcome of many different cancers, including Hodgkin lymphoma. Even small amounts of exercise are helpful. Keep in mind that it's better to exercise more frequently in smaller amounts than to exercise for long periods less often.
Sleep well: We don't know about the effects of sleep disorders on Hodgkin disease, but we know that with breast cancer these conditions may reduce survival. Talk to your oncologist if you are having this very common side effect of treatment.
Create a cancer survivor care plan: When you are done with treatment, make sure that you and your doctor fill out a survivor care plan. The risk of secondary cancers is real after Hodgkin treatment, and may even be increasing. Your doctor may recommend earlier or more frequent screening for cancers such as breast cancer and follow up on symptoms of other cancers should they occur.
Hodgkin Lymphoma: Often Curable, Yet a Challenging Disease
It might seem funny to someone who has not experienced cancer, but there is almost a competition between people with different forms of cancer, or at least between those with higher survival rate and lower survival rate cancers. Those with cancers with lower survival rates may consider more survivable cancers as less challenging.
Keep in mind that even though Hodgkin lymphoma is more curable than many other cancers, facing any cancer is terrifying. Having your mortality thrown in your face is something those without cancer may not understand and it doesn't matter if the cancer has a 99 percent survival rate or a 2 percent survival rate. We should note as well that, even when curable, the treatments to control Hodgkin lymphoma are challenging at best. Chemotherapy may continue much longer, and especially with stem cell transplants, to a greater degree, than with many other cancers. There is also the issue of long-term side effects of Hodgkin lymphoma, such as secondary cancers, which will require lifelong monitoring.
As a final note, if you or a loved one have gone through treatment for Hodgkin disease, it's important to talk to your doctor about survivorship. Many cancer clinics now have active cancer rehabilitation programs in which the late effects of cancer treatment, ranging from chronic pain to anxiety, are fully addressed.
Limiting processed foods and red meats can help ward off cancer risk. These recipes focus on antioxidant-rich foods to better protect you and your loved ones. Sign up and get your guide!
Ahmadzadeh, A., Yekaninejad, M., Jalili, M. et al. Evaluating the Survival Rate and the Secondary Malignancies after Treating Hodgkin Lymphoma Patients with Chemotherapy Regimens. International Journal of Hematology Oncology and Stem Cell Research. 2014. 8(2):21-26.
American Cancer Society. Cancer Facts & Figures 2017. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html
Brenner, H., Gondos, A., and D. Pulte. Survival Expectations of Patients Diagnosed with Hodgkin Lymphoma in 2006-2010. The Oncologist. 2009. 14(8):806-813.
National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER Cancer Statistics Review (CSR) 1975-2014. Released April 14, 2017. https://seer.cancer.gov/csr/1975_2014/
B-Cell Lymphomas: Types and Treatment
What Is Nodular Sclerosing Hodgkin Lymphoma?
What's the Survival Rate for Each Stage of Lung Cancer?
What Determines the Outlook for High Grade Non-Hodgkin Lymphoma?
What Survival Rate Really Means With Cancer
The 9 Factors That Impact Small Cell Lung Cancer Survival Rates
5 Major Differences Between Leukemia and Lymphoma
What Is Stage 1 Lung Cancer Life Expectancy?
Learn Exactly What Median Survival Means
Long-Term Effects of Radiation Therapy Everyone Should Know
An Overview of Follicular Lymphoma
How a Prognosis Can Help With Better Healthcare for You
How Long Can You Live With Stage 4 Breast Cancer?
10 Rational Reasons to Stop Smoking After a Diagnosis of Cancer
Stage 4 Lung Cancer Life Expectancy
Overview of Mixed Cellularity Hodgkin Lymphoma

redpajama_set_name: RedPajamaCommonCrawl


text:
The 2010s 2017 Archive: (December) (November) (October) (September) (August) (July) (June) (May) (April) (March) (February) (January)
This is a topic from the The 2010s forum on inthe00s.
Subject: New EDM songs that don't sound like Mid '10s pop EDM?
Written By: bchris02 on 04/18/17 at 8:47 pm
Does anybody know of any new EDM songs that don't sounds like the overproduced, bland pop EDM sound that has dominated Top 40 since 2013? Anything early '10s style (that's new) or maybe something totally different?
Subject: Re: New EDM songs that don't sound like Mid '10s pop EDM?
Written By: #Infinity on 04/18/17 at 9:42 pm
I suppose this may be a decent example. This group used to be huge in Europe during the Y2K era, but they've reformed to record a new studio album, set for release on the 21st, to celebrate their 20th anniversary. The songs they've put out so far have the same melodic sensibilities of their classic hits, but with more up-to-date production.
Here's the video to the leadoff single:
http://youtube.com/watch?v=xRb4xqFpOvY
Thanks for posting this. I like it!
Written By: HazelBlue99 on 04/18/17 at 9:59 pm
This isn't brand new (it was released in Late 2014), but it is a song by an Australian group called Peking Duk. Personally, I don't think it sounds as over-produced as most of the EDM songs which were in the Top-40 during the Mid 2010s. I know that you wouldn't be aware of the band or the song, but this was the only EDM song that I could think of, that doesn't like "Closer" or the other ilk. I'm not an expert on EDM. :P
http://www.youtube.com/watch?v=XrL9TsGVyxs
Written By: #Infinity on 04/18/17 at 10:39 pm
You're welcome, glad you enjoy it! :)
Written By: 2001 on 04/18/17 at 10:46 pm
Do you care what language it's in?
This was the peak of EDM for me.
13o1i-cgTOA
Written By: bchris02 on 04/18/17 at 11:20 pm
Awesome song! Thanks!
Written By: Slim95 on 04/20/17 at 3:34 pm
That EDM you speak of actually started to get big in popularity last year in 2016, along with dancehall music. 2016 had a very slight shift in music.
Written By: Shemp97 on 04/20/17 at 4:04 pm
Yep. My sister and I were listening to her since the late 00s 8)
Written By: 2001 on 06/10/17 at 5:46 pm
Chris, check out Roulette by Katy Perry. I think you'll like it!
Thanks. I do really like it.


Horst is an application to monitor wireless traffic. It gives you statistics about the wireless medium, and have a nice curses UI for a human to read.
assuming you have named the monitor wlan0.
This page was last modified on 5 April 2011, at 21:28.


text:
Medreach Pty Ltd
Public health & consumer activist
Publications / Talks
Teaching & supervision (Monash University)
← Souvenaid update
Therapeutic Goods Amendment (Pharmaceutical Transparency) Bill 2013 torpedoed →
Complementary Health Care Council (CHC) rant against critics
Posted on June 17, 2013 by Dr Ken Harvey
"These sceptics have successfully used the media, and abused the advertising complaints system, to force the Department of Health and the TGA into tightening the regulation of complementary medicines into a fully-fledged medical model of regulation, including an evidence regime that could only be met by registered medicines".
Wendy Morrow, CHC [this and the following article from which the quote comes is copied in the public interest]
From: Special Report: TGA between a rock and a hard place on CMs
http://www.pharmainfocus.com.au/feature.asp?featureid=534
The TGA is regularly criticised for failing to control 'rogue' complementary medicines makers who break promotional regulations but appear to suffer few consequences, but is it hamstrung by a confused and misdirected regulatory system?
"Supplement regulation by TGA is completely cactus" shouted the headline in online journal The Conversation. It was not the only story and/or commentary stirred up by what is seen as the most recent failure by the medicines regulator to clamp down on weight-loss products.
As a result of events around the cancellation of Swisse Ultiboost Appetite Suppressant and it's effective reinstatement under another name, the TGA has lately suffered a barrage of criticism, branded a watchdog that is too scared to go out in the rain and subjected to mockery courtesy of the ABC's comedy-inclined consumer show, The Checkout.
While that program's coverage of the Swisse controversy has earned its makers a defamation suit, the TGA has chosen not to respond to this latest in a series of attacks on its credibility as a regulator when it comes to the complementary sector.
Pharma in Focus asked the industry associations that represent the CM sector to answer some questions about their view of the TGA's performance, and the difficulties under which the regulator may be operating when it comes to controlling the promotion of these products
Sound system?
"The architecture of the regulatory system in Australia for complementary medicines is sound. It is consistent with a risk management approach on which low risk products expect a light touch," says Australian Self-Medication Industry executive director, Deon Schoombie.
But he adds that his organisation does not think the system is perfect and sees opportunities for improvement.
In particular, says Dr Schoombie, the regulator needs to clarify requirements so that no sponsor can claim they don't know the rules. For example, guidelines for levels of evidence are, in ASMI's view, not clear.
"This is something we are working with the TGA and consumers to resolve as part of the Blueprint reforms. This work is almost complete but what will happen in an election year is anybody's guess. There are very few parliamentary sitting days left," says Dr Schoombie.
The Complementary Healthcare Council's executive director, Wendy Morrow, sees the architecture as lop-sided with a bias towards treating CMs and a sub-set of prescription drugs.
"Complementary medicines differ from pharmaceutical drugs, and as such, should be regulated differently," she says. "They have never claimed to be a medical solution to a medical problem; rather, they look at how to assist the overall wellness of consumers to help improve daily lives and help prevent us all from falling sick (or at least reducing the duration) by maintaining a healthy balance."
The CHC goes so far as to call for a separate regulatory system for CM's, advocating for Australia to implement an "appropriate Regulatory Framework for Complementary Medicines under an Office of Complementary Medicines Authorisation and Complementary Medicine-relevant legislation.
Such a system would "adopt the principles of minimum effective regulation as opposed to risk elimination or risk aversion, a strategy based on co-regulatory and self-regulatory options that offer the most cost effective regulatory governance and administration," the group says.
Media exploitation
Dr Morrow says the current complex and confused regulatory system has allowed the media to give CM promotion a bad name.
"The TGA state that as part of their goals to enhance the complementary medicine regulatory framework is being seen to ensure that it remains adaptable to community and industry expectations. Potentially as a consequence of this goal, one of the main problems faced by the regulator is trying to negate the criticisms of a handful of complementary medicine sceptics," she says.
In particular, she says, "Misleading compliance information released by the TGA in 2011 has been continuously and irresponsibly published in every article that seeks to call for tighter reform of complementary medicines. The compliance information has since been acknowledged as being based on a statistically insignificant sample size of products that were targeted for audit review."
The CHC cites an Australian National Audit Office report on the regulation of CMs as saying, no statistically valid, general conclusion can be drawn about the state of compliance. "In fact, the only true conclusion that could be drawn from this statistic is that it provides evidence as to the efficacy of targeted audits," says Dr Morrow.
Dr Schoombie says a strong regulatory system is all very well but without enforcement, it becomes a paper tiger. "We can develop the best system on the planet but if not enforced and we don't have a compliance system in place, it's no good."
Despite strong concern about what it regards as a growing tendency towards over-regulation, the CHC agrees. "The CHC believes that increased requirements, in the absence of evidence of any specific consumer safety concern, do not constitute best practice regulation. The CHC does however, support more stringent enforcement action against companies that have made little or no attempt to comply with the regulations, or where a true safety concern is identified," says Dr Morrow.
She adds that TGA resourcing needs to be improved. "The CHC strongly considers that the TGA require more resources. In particular our first recommendation to government outlined in our Pre-budget Submission 2013/14, was to provide the industry regulator, the Office of Complementary Medicines within the TGA with additional resources to enable more comprehensive, timely and consultative development and implementation of appropriate regulatory reform, including the planned reforms to the advertising framework."
But while agreeing there may be resourcing issues at play, Dr Schoombie says "industry is sensitive about paying more" without knowing what extra value it would be getting.
"If the TGA could demonstrate added value, that fees translate into outcomes then industry would be willing to discuss. It's the kind of conversation we should have because there is much room for improvement in compliance."
However, he adds, ASMI is against the idea that everything should be pre-vetted for quality, safety and efficacy. "This may sound good but it's completely impractical."
But as the debates over pushing the promotional boundaries continue to surface, both organisations agree that sanctions on rogue operators need beefing up.
Dr Schoombie says that ASMI recognises that there are 'cowboys' and that the possibility of simply re-listing under a different name a product that has been de-listed, means the current system is not effective. "We need incentives to comply through decent penalties and sanctions," and they need to have a commercial effect, he adds.
"If you know there's a $10,000 fine or that sort of thing, you may think again before re-listing."
However, he sees no role for the Australian Competition and Consumer Commission (ACCC) in regulating CM advertising. "My sense is that the ACCC is going after the big boys. The TGA is the right way to do it."
Dr Morrow is less dismissive of the competition regulator, acknowledging there is an argument for the ACCC taking more of a role. "There is an argument to say that most of the things covered by the TGAC are already covered by the Australian Consumer Law, and that the TGA should be responsible for authorising the product, and writing the code, but the ACCC might be best placed authority to administer the code either with or without advertising pre-approval.
"There is an implicit duplication in having advertising resources in TGA and ACCC, when the job could be more efficiently done if they were in one place. Arguably monitoring and reviewing advertising is not the TGAs forte since most therapeutic goods are not advertised to consumers."
But, she says, there is an easy answer to the 'cowboy' problem, the only problem is that the TGA does not back it.
"An easy answer to stopping rogue companies entering the Australian market and listing their products on the ARTG would be to require all sponsors of products in Australia to nominate an industry code at the time of listing a product on the ARTG. However, the TGA has stated that this is not supported because it departs from the self-regulatory model. It should be noted that prescription medicines, not permitted to advertise directly to consumers, is the only sector that is actually self-regulated."
Dr Schoombie supports a similar position. "For prescription pharmaceuticals abiding by the Medicines Australia Code of Conduct is a condition of market approval. We would like to see something similar but, while there have been advocates for this, so far there doesn't seem to be an appetite for it on the government side. From a level-paying-field point of view, this merits discussion," he says.
In the meantime, both sides await the outcome of proposed amendments to the Therapeutic Goods Act that if passed would mean increased TGA powers to suspend, cancel and remove goods from the ARTG in light of unacceptable presentation of the goods, but with only two weeks of sittings left before the election, there seems little prospect of change before next year at the earliest.
Nick Lush
About Dr Ken Harvey
Public Health Physician, Medical activitist
View all posts by Dr Ken Harvey →
This entry was posted in Complementary medicine, Natural Therapies and tagged CHC, Complaint Resolution Panel, Regulatory Reform, Swisse Vitamins, TGA. Bookmark the permalink.
Vitamins are not a substitute for a healthy diet
Monash BME2032 Work Integrated Learning (WIL) students
Can a few zaps a day keep the pain away?
Monash SPHPM Summer School Scholarship Student Research 2019
Skepticon 2019, TGA, ACCC, Regulatory Panel Discussion
TGA decision to grant Special Access Scheme B approval for suspended breast implants
ACCC
AMHC
Chiropractic Board
Complaint Resolution Panel
Dr Jacqui Forrester
Dr Tom Goyer
food-medicine interface
Friends of Science in Medicine
FSANZ
Geoff Jowett
Health Practitioner Regulation National Law Act
Ian Rossborough
Medical Weightloss Institute
Medicines Australia
MMD Review
MWI
Pharmacare Laboratories
Senate Community Affairs Legislation Committee
TGACC
TGA Complaint system
TGACRP
Therapeutic Goods Act
Therapeutic Goods Advertising Code
Therapeutic Goods Amendment (2017 Measures No. 1) Bill 2017


Designed for little helpers to put on by themselves. Our apron is great for food prep, painting, gardening, and all things messy. We love this mod butterfly print, giving your little one a sophisticated look in the kitchen. Look for the coordinating infinity scarf, tote and pocket bib!


This rare and extremely limited wine is made only when nature's good fortune allows the harvesting of grapes affected with botrytis cinerea, or noble rot. The white grapes destined for this wine were still on the vine in mid-November, slowly dehydrating and accumulating the noble rot essential for achieving its exquisitely rich honey and apricot profile.
Aromatically complex, 2012 Shahpar exudes a classic profile of juicy apricot, honeysuckle and orange marmalade punctuated with vivacious citrus fruits and spice.
The persistent pear, apple blossom and lemon oil on entry fall away to toasted coconut and vanilla bean with a delicate, pastry cream-like texture. For all its marked sweetness, an uplifting freshness is lent by the wine's predominantly hillside origins; it finishes with great depth, displaying hints of mineral and lemongrass.